EP4051300A1 - Composition pour la prévention et le traitement de maladies du système respiratoire - Google Patents

Composition pour la prévention et le traitement de maladies du système respiratoire

Info

Publication number
EP4051300A1
EP4051300A1 EP20796836.3A EP20796836A EP4051300A1 EP 4051300 A1 EP4051300 A1 EP 4051300A1 EP 20796836 A EP20796836 A EP 20796836A EP 4051300 A1 EP4051300 A1 EP 4051300A1
Authority
EP
European Patent Office
Prior art keywords
composition
composition according
snail
treatment
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20796836.3A
Other languages
German (de)
English (en)
Inventor
Umberto DI MAIO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neilos SRL
Original Assignee
Neilos SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neilos SRL filed Critical Neilos SRL
Publication of EP4051300A1 publication Critical patent/EP4051300A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Definitions

  • composition for the prevention and treatment of diseases of the respiratory system Composition for the prevention and treatment of diseases of the respiratory system
  • the present invention relates to a composition
  • a composition comprising an association of a snail extract and Karaya gum useful for the prevention and treatment of diseases of the respiratory system.
  • the composition is particularly effective thanks to the synergistic action of its components.
  • the respiratory system is made up of different anatomical structures that serve its correct function.
  • the former are made up of the nose, pharynx and associated structures, while the latter are made up of the larynx, trachea, bronchi and lungs, whose real respiratory surface is made up of the alveoli.
  • This complex system of organs serves to prepare the air for its entry into the lungs, by filtering any particulate matter, heating and humidification. Particles larger than 10-15 microns can be blocked at the level of the nasal cavities, thanks to the whiskers and the presence of mucus that traps these particles in addition to the precipitation by turbulence, mediated by the turbinates that divert the direction of the air.
  • the mucus stratifies above the peri-ciliary fluid, in which the vibrating cilia of the cells of the epithelium are immersed. Particles of about 10 microns arrive in the trachea, are trapped in the mucus and then eliminated by the ciliary movement. Particles of 2-5 microns settle in the terminal bronchioles by gravitational precipitation, while those smaller than 2 microns are removed by the alveolar macrophages and removed from the pulmonary lymphatic system.
  • the entire respiratory tract is made up of epithelial cells that differ in type and function along the tracheobronchial tree.
  • Columnar ciliated cells characterize the airways from the trachea to the terminal bronchioles. From their apical surface the cilia protrude having the task of moving with a cleaning effect on the mucus and on any inhaled particles.
  • the mucous goblet cells are responsible for the secretion of mucus, which is useful for maintaining the correct humidity of the epithelium and for trapping particulate matter. They are present in the broader tracts of the airways below the small bronchi but have not been found in the bronchioles.
  • All components of the respiratory system can be exposed to a series of diseases, of different etiology, often supported by different pathogenic microorganisms which, becoming predominant in the microenvironment and on the flora normally present, determine the disease and, consequently, lead to a reduced functionality.
  • EXAMPLES OF AFFECTIONS OF THE RESPIRATORY TRACT Depending on the area of the respiratory system concerned, different pathological conditions can be distinguished characterized by inflammation due to viruses, bacteria or fungi.
  • cough reflex in itself is an important defense capable of promoting the elimination from the respiratory tract of particulate matter that could contain allergens or pathogenic microorganisms. Under normal conditions, cough plays a primary role in protecting the airways and lung parenchyma.
  • Cough is commonly classified into acute, subacute and chronic cough.
  • the duration is up to 3 weeks and in most patients, it is due to upper respiratory tract infections, acute bronchitis or tracheobronchitis due to bacterial or viral infections.
  • This type of cough usually passes within a couple of weeks along with the complete resolution of the infection.
  • Subacute cough is characterized by a duration of between 3 and 8 weeks and is generally related to specific infections (such as M. pneumoniae) where a greater response at the bronchial level can persist for longer even after the infection has resolved.
  • Chronic and persistent cough is usually due to other types of causes such as cigarette smoking, the use of ACE inhibitors, asthma, gastroesophageal reflux disease and cystic fibrosis.
  • ACE inhibitors drugs which act centrally by inhibiting the cough center
  • N-acetylcysteine which acts as a mucolytic by increasing the smoothness and therefore the elimination of mucus
  • anticholinergic drugs such as tiotropium and ipatropium which are taken by inhalation and inhibit bronchoconstriction and mucus hypersecretion by antagonizing the binding of acetylcholine to muscarinic receptors in the lung.
  • Pharmacological treatment must be well thought out and evaluated based primarily on the cause that led to the appearance of the cough as well as on the severity and persistence of the symptom. However, all pharmacological treatments, especially if used for prolonged periods, can cause side effects of varying degrees and importance that reduce patient compliance.
  • Rhinitis, allergic rhinitis and nasopharyngitis cold
  • Rhinitis is an inflammatory process that affects the mucous membrane of the nasal cavities and is divided into acute and chronic.
  • Acute rhinitis is generally supported by viruses, including Rhinovirus, Coronavirus, influenza and parainfluenza viruses, RSV, Coxsackie virus, ECHO virus, and adenovirus.
  • Contagion occurs by direct contact with the sick subject who, in the peak of maximum contagiousness (generally the first day), has 500-1000 virions per ml of secretion, which he emits through coughing and sneezing.
  • Bacterial superinfections are possible leading to complications such as ear infections and sinusitis.
  • the common Rhinovirus cold causes acute symptoms in the first 3-4 days, while cough and other symptoms persist for 7-10 days. There is an excess of mucous secretions which are fluid and transparent, and become purulent and foul-smelling in the case of bacterial overlap.
  • the chronic form is generally secondary to sinusitis, deviations of the nasal septum and hypertrophic adenoids.
  • Allergic rhinitis is due to the subject's exposure to substances that cause a mediated IgE reaction, characterized by excessive production of fluids, intranasal itching, sneezing and obstruction.
  • IgE binds to mast cells which release large quantities of histamine, responsible for all the morbid manifestations.
  • the common cold is known as nasopharyngitis, an inflammation of the mucous membranes of the nose and pharynx that may be due to flu or parainfluenza viruses or cold viruses such as adenoviruses. Cold can also be a trigger of the disease as it reduces the effectiveness of immune processes.
  • Sinusitis is inflammation of the mucous membrane that lines the paranasal sinuses, bony cavities located in the facial massif that are in communication with the nasal cavities and, therefore, can become infected for the same causes that cause rhinitis.
  • Sinusitis can be divided into acute viral or bacterial (up to 4 weeks), chronic (over 12 weeks) and recurrent acute (at least 4 episodes per year with resolution).
  • a healthy nasal sinus is sterile, characterized by appropriate drainage of mucus and free passage of air. Ciliary abnormality or immobility result in inhibition of drainage resulting in sinusitis. Predisposing factors for this pathology are an immunocompromised state, deviation of the nasal septum, nasal polyps, tumors, trauma and fractures, cocaine abuse and the presence of foreign bodies.
  • An acute viral form can be prone to bacterial superinfection.
  • the bacteria commonly responsible for these infections are Streptococcus pneumoniae, non-typable Haemophilus influenzae, Moraxella catarrhalis.
  • Pseudomonas aeruginosa is most frequently present in sinus infections from HIV and cystic fibrosis.
  • Some genera of fungi such as Candida, Aspergillus, Blastomyces, Coccidioides, Rhizopus, Histoplasma and Cryptococcus can cause sinusitis in immunocompromised patients.
  • the signs and symptoms of acute rhinosinusitis consist of: mucopurulent discharge from the nose, nasal obstruction, congestion, facial pain, pressure in the sinuses involved, hyposmia, anosmia, fever, feeling of pressure or “plug” in the ears, pain in the teeth.
  • Sinusitis often resolves spontaneously and the treatment is predominantly symptomatic.
  • the decongestant treatment serves to reduce edema, improve the drainage of excess mucus and maintain the patency of the sinus ostia.
  • a good result can be obtained from the local application of hypertonic saline solution both in the treatment of the acute bacterial form and in the acute recurrent one and in the chronic one and also in prevention.
  • antibiotics must take into account the production of beta lactamase and the presence of drug-resistant pneumococci.
  • Infection can be caused by viruses (such as Epstein-Barr) and bacteria, in particular group A beta-haemolytic Streptococcus pyogenes is the most frequent in pediatric forms, but Mycoplasma pneumoniae and Chlamydia pneumoniae are also found in adults and children.
  • viruses such as Epstein-Barr
  • group A beta-haemolytic Streptococcus pyogenes is the most frequent in pediatric forms, but Mycoplasma pneumoniae and Chlamydia pneumoniae are also found in adults and children.
  • the forms transmitted by sexual contact and sustained by Neisseria gonorrhoeae and those by Corynebacterium dyphtheriae (form reduced by the use of the vaccine) must also be considered.
  • H. influenzae type b H. influenzae type b
  • streptococci staphylococci or thermal trauma. It is manifested by pain in the ears (in adults), dysphonia, while fever is absent in up to 50% of cases and can develop in a late stage. T reatment is antibiotic when bacteria are the cause of the disease, while intubation may be required in the case of severe airway obstruction.
  • Non-infectious causes can be tumors, thermal or caustic trauma, and gastroesophageal reflux disease (GERD).
  • Laryngitis has symptoms that last 3-4 days and, unless bacteria are present, no antibiotics are used.
  • Bronchitis is a frequent inflammation of the bronchi which manifests itself as cough, shortness of breath, and chest pain. Bronchitis is divided into acute and chronic. In the first case, the cough lasts about three weeks and is caused in 90% of cases by a viral infection that can occur as a result of contagion with other infected people. Predisposing risk factors can be cigarette smoke or other sources of environmental pollution.
  • Chronic bronchitis is characterized by coughing for three months a year for at least two episodes a year and cigarette smoking together with other genetic or environmental causes are the main triggers. As a rule, except in special cases, no antibiotics are used but steroid anti-inflammatory drugs, paracetamol to compensate for a possible increase in temperature and bronchodilators such as salbutamol to improve breathing.
  • the subject of the present invention is a composition comprising an association of snail extract and Karaya gum for the prevention or treatment of respiratory diseases.
  • the components of the association according to the present invention are all known components, widely used in therapy.
  • the snail has an external shell (limacella) (element having a protective function and useful to distinguish the various species) in the shape of a spiral, hence the name "Helix”.
  • the Helix genus is the one of greatest gastronomic and commercial interest.
  • the main farmed species are: Helix Aspersa Muller, Helix Pomatia L, Helix Vermiculata.
  • the snail extract (snail meat) which is obtained from the entire body of the mollusk with the exception of the external limacella is known for its consumption in the food sector.
  • the composition includes about 80% water, about 13% protein, 4% carbohydrates and low fat (0,6%).
  • lysine, leucine and valine are present in higher concentrations while glutamic acid, alanine and aspartic acid are the most abundant non-essential amino acids.
  • glutamic acid, alanine and aspartic acid are the most abundant non-essential amino acids.
  • vitamins A, E, B1 , B2, B3 and B6 are the most abundant non-essential amino acids.
  • snail mucopolysaccharide commonly called “slime” which is a secretion produced by some glands located in the foot. It has been used for several years in medicine and in the cosmetic industry, due to its strong nourishing and moisturizing properties.
  • the substance used in the cosmetic sector is the slime produced by the Helix Aspersa variety, the most common species of snail in the Mediterranean basin, including the Italian peninsula.
  • the substance is a clear, limpid or slightly opalescent liquid; it is completely miscible in water, insoluble in vegetable or mineral oils, dispersible in oil-in-water emulsions.
  • the snail slime is suitably collected, filtered, concentrated and dried and is used for various therapeutic activities.
  • Helicidin is a mucoglycoprotein from the drool used as a cough suppressant, therefore of particular interest for the present invention.
  • An in vitro study shows that helicidin has a spasmolytic effect on tracheal smooth muscle isolated from guinea pigs, in part due to the induction of prostaglandin E2 production.
  • a further double-blind clinical study confirmed the antitussive effect of helicidin through polysomnograph evaluation of nocturnal coughing episodes in patients with chronic obstructive pulmonary disorders.
  • the study lasted 5 days; in the first two nights, patients were analyzed to recruit those with more than 20 coughing episodes.
  • the administration of helicidin syrup at 10% or placebo in two doses of 15 ml 3 times a day for 3 consecutive days was started and coughing episodes on the fourth and fifth night were then evaluated.
  • the number of coughing episodes recorded on the second night before administration was used as a control.
  • this substance contained in the drool is recommended for the treatment of cough, especially for patients in whom opioid agents and antitussive antihistamines are contraindicated.
  • the moisturizing and antitussive action of snail extract appears to be of interest in order to alleviate signs and symptoms typical of upper respiratory tract diseases.
  • Karaya gum is obtained from the exudates of Sterculia urens, a large and bushy tree belonging to the Sterculiaceae family, which grows in the dry and rocky forests of central and northern India.
  • Karaya gum has the appearance of a fine powder, a gray- pink color and a slightly acetic smell and taste; combined with some compounds such as glycols, it has the ability to form thin films when plasticized with these compounds.
  • Most of the Karaya gum on the market is obtained from Sterculia urens, all parts of the tree have this soft gum when cut.
  • Karaya gum is made by carbonizing or scarring the tree trunk and removing a piece of bark or drilling holes in the trunk.
  • an object of the present invention is a composition comprising the association of snail extract and Karaya gum mixed with one or more suitable acceptable carriers.
  • the snail extract can be present in an amount between 10 mg and 20000 mg, preferably between 50 mg and 10000 mg, even more preferably between 100 mg and 8000 mg.
  • Karaya gum can be present in an amount ranging from 1 mg to 10000 mg, preferably from 10 mg to 7000 mg, even more preferably from 20 mg to 5000 mg.
  • composition object of the present invention comprises the association of snail extract and Karaya gum in admixture with one or more suitable acceptable carriers.
  • Suitable acceptable carriers are those commonly known to those skilled in the art for the preparation of compositions for oral administration such as syrups, solutions, suspensions, powders or granulates, tablets, capsules, pellets.
  • such acceptable carriers may consist of binders, diluents, lubricants, glidants, disintegrating agents, solubilizers (wetting agents), stabilizers, dyes, anti-caking agents, emulsifiers, thickeners and gelling agents, coating agents, humectants, sequestrants and sweeteners.
  • diluents can be: magnesium carbonate, microcrystalline cellulose, starch, lactose and sucrose.
  • the main lubricants used are magnesium stearate, stearic acid and sodium stearyl fumarate.
  • colloidal silica and magnesium silicate can be mentioned; as disaggregating agents, cross-linked polyvinylpyrrolidones and sodium glycolate starch can be mentioned; as solubilizers, surfactants such as TWEEN or sodium lauryl sulfate can be mentioned and, as stabilizers, all classes of preservatives (sorbic acid and derivatives, benzoic acid and derivatives, parabens), antioxidants (ascorbic acid and derivatives, tocopherol) and acidifiers (phosphoric acid, tartaric acid) can be mentioned.
  • preservatives sorbic acid and derivatives, benzoic acid and derivatives, parabens
  • antioxidants ascorbic acid and derivatives, tocopherol
  • acidifiers phosphoric acid, tartaric acid
  • the thickeners and gelling agents can be carrageenan, pectins and starches; coating agents may include, for example, waxes and derivatives; anti-caking agents can include calcium or magnesium carbonate; humectants can include sorbitol and mannitol; sequestrants can include EDTA and derivatives; sweeteners can include aspartame and acesulfame potassium.
  • the composition object of the present invention is preferably a liquid or solid composition for oral use, even more preferably a syrup, an aqueous solution, a suspension, a powder or granulate, a tablet, a capsule or pellet.
  • the composition object of the present invention can be a medical device, a food supplement, a nutraceutical, dietary and nutritional composition, a food product, a beverage, a nutraceutical, a medicament, a medicated food, a pharmaceutical composition or a food for special medical purposes or even in the form of simple, complementary, complete feed, intended for particular nutritional or medicated purposes.
  • compositions referred to in the present invention are particularly effective in counteracting the pathologies of the respiratory system thanks to the synergistic action of their components.
  • composition object of the present invention exhibits a valid synergistic effect, in particular, when the snail extract is present in an amount between 10 mg and 10000 mg, and Karaya gum is present in an amount between 10 mg and 5000 mg.
  • a further object of the present invention is therefore a composition comprising the association of snail extract and Karaya gum in admixture with one or more suitable carriers acceptable for use in the prevention and / or treatment of respiratory tract diseases in humans as well as in animals.
  • the compositions object of the present invention are particularly effective in the treatment of cough, rhinitis, allergic rhinitis, nasopharyngitis or cold, rhinosinusitis, sinusitis, pharyngitis, epiglottitis, laryngitis and bronchitis, allowing at the same time to obtain an anti-inflammatory, antioxidant and antimicrobial effect thanks to the action synergistic of their components.
  • the natural compounds extracted from snail and Karaya gum of the association object of the present invention are essential to obtain the desired effectiveness in the prevention and treatment of respiratory tract diseases.
  • composition object of the present invention allows to obtain simultaneously a film-forming effect and an antibacterial effect.
  • - Karaya gum enhances the film-forming effect as it forms a barrier on the mucous membrane of the throat, shielding it from any pathogens and therefore also exerting an antibacterial action.
  • the synergistic activity of the aforesaid active ingredients can be studied by using any in vitro and / or in vivo test known in literature capable of evaluating the film-forming and antibacterial activity of the compositions according to the present invention and / or of the compositions of comparison.
  • in vitro assays such as those determining the traction force, the shear stress, the adhesion weight method, fluorescent probe method, flow channel method, mechanical spectroscopic methods, liquid film drop method, viscometer test, adhesion number, in vitro substance release studies.
  • an in vitro model proposes to test the present composition for its mucoadhesive and film-forming effect.
  • the protocol involves using liposomes coated with 4 different polymers, namely alginate, snail extract, Karaya gum and a blend of snail extract and Karaya gum.
  • Mucoadhesive is evaluated using a new in vitro method that allows liposomes to interact with a mucus-producing HT29-MTX cell line without applying any external force, and then determine mucoadhesive capacity by fluorescence intensity.
  • the aim is to demonstrate that liposomes coated by the mixture of snail extract polymers and Karaya gum achieve higher mucoadhesivity than alginate coated and single component liposomes.
  • the inclined plane model can also be used.
  • the steel top is positioned horizontally and the temperature is set at 60 e C before the start of the run.
  • a few ml of sample (or deionized water for the controls) are placed at the predefined distance on the table and left to rest for a few minutes.
  • the table is tilted at 45 °C and the sample detached at the end of the run is weighed.
  • the sample falls into a petri dish and is weighed with automatic recordings at set intervals (e.g. 60 seconds).
  • in vitro assays are suitable such as broth-dilution (by calculating the MIC, minimum inhibitory concentration and MBC, minimum bactericidal concentration) and diffusion in agar (where a standardized concentration of the sample is applied in a culture broth of bacteria and the diffusivity of the sample within the medium is calculated).
  • An in vivo model proposes to test the present invention to evaluate its antitussive effect on animal models (e.g. guinea pigs or others) with cough caused by inhalation of irritating agents such as capsaicin, citric acid or others.
  • animal models e.g. guinea pigs or others
  • irritating agents such as capsaicin, citric acid or others.
  • Anesthetized animals are exposed to a nebulized aqueous solution of the irritating agent and during exposure they are constantly observed to assess the number of tussive episodes. After establishing how soon the tussive episodes occur, the duration of exposure to the irritant agent is fixed.
  • This model proposes to pre-treat animals with the single active ingredients or their combination (object of the present invention) orally, 30 minutes before inhalation with capsaicin, to demonstrate how the number of tussive episodes is significantly reduced by the synergistic action of the components compared to the same tested individually.
  • compositions are prepared according to conventional techniques such as mixing.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une composition qui comprend une combinaison synergique d'extrait d'escargot et de gomme de Karaya pour la prévention et/ou le traitement de maladies des voies respiratoires.
EP20796836.3A 2019-10-31 2020-10-30 Composition pour la prévention et le traitement de maladies du système respiratoire Pending EP4051300A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102019000020154A IT201900020154A1 (it) 2019-10-31 2019-10-31 Composizione per la prevenzione e il trattamento di affezioni dell’apparato respiratorio
PCT/EP2020/080488 WO2021084058A1 (fr) 2019-10-31 2020-10-30 Composition pour la prévention et le traitement de maladies du système respiratoire

Publications (1)

Publication Number Publication Date
EP4051300A1 true EP4051300A1 (fr) 2022-09-07

Family

ID=69811604

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20796836.3A Pending EP4051300A1 (fr) 2019-10-31 2020-10-30 Composition pour la prévention et le traitement de maladies du système respiratoire

Country Status (3)

Country Link
EP (1) EP4051300A1 (fr)
IT (1) IT201900020154A1 (fr)
WO (1) WO2021084058A1 (fr)

Also Published As

Publication number Publication date
IT201900020154A1 (it) 2021-05-01
WO2021084058A1 (fr) 2021-05-06

Similar Documents

Publication Publication Date Title
RU2520745C2 (ru) Лекарственная композиция для лечения бронхита и способ ее получения
US9861647B2 (en) Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
EP3687557B1 (fr) Composition destinée à la prévention et/ou au traitement de troubles des voies respiratoires
EP2251016B1 (fr) Utilisation topique de l'acide hyaluronique filmogène pour le traitement et la prophylaxe des pathologies des voies respiratoires
US20160331794A1 (en) Composition for use in the treatment of persistent cough
JPH08337532A (ja) 医薬組成物
EP1367970A1 (fr) Polymeres alkylaryl polyether alcool pour ameliorer la respiration nasale
EP3749348B1 (fr) Composition pour la prevention et le traitement de maladies respiratoires
EP4051300A1 (fr) Composition pour la prévention et le traitement de maladies du système respiratoire
EP3738589B1 (fr) Composition pour la prévention et/ou le traitement de maladies de la muqueuse oropharyngienne
CA2701388C (fr) Glycerophosphate de calcium pour le traitement et la prevention de maladies ou de pathologies respiratoires
WO2019141540A1 (fr) Composition pour le traitement de maladies des voies respiratoires
CN111615384A (zh) 鼻窦炎的治疗方法
WO2019180635A1 (fr) Composition à utiliser pour le traitement de maladies respiratoires et oropharyngées
WO2021234660A1 (fr) Composition pour la prévention et le traitement de maladies du tractus respiratoire et en tant que stimulant du système immunitaire
IT202200021717A1 (it) “Composizione per la prevenzione e il trattamento delle affezioni delle vie respiratorie e come stimolante del sistema immunitario”
JP7166929B2 (ja) イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの使用
IT202200021252A1 (it) “Composizione per la prevenzione e il trattamento delle affezioni delle vie respiratorie”
JP6232631B2 (ja) 生体皮膜剤
WO2022168019A1 (fr) Composition à action immunostimulante utile pour la prévention et le traitement de maladies respiratoires
ITBO20090487A1 (it) Composizione sciroppo uso orale a base di acetil-cisteina ed estratti naturali per il trattamento e profilassi di patologie delle vie respiratorie
KR102027176B1 (ko) 〔（（1ｒ,2ｓ,5ｒ）―2―이소프로필―5―메틸―시클로헥산카르보닐）―아미노〕―아세트산 이소프로필 에스테르와 관련 화합물 및 요법에서 그의 용도
JPWO2017177966A5 (fr)
AU2002247032A1 (en) Alkyl aryl polyether alcohol polymers for improvement of nasal breathing

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220429

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240510